Provectus Biopharmaceuti... (QB) Stock Price - PVCT

0.0002 (0.45%)
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Provectus Biopharmaceuticals Inc (QB) PVCT OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.0002 0.45% 0.0442 0.04 0.0495 0.04 0.044 12:49:01
Bid Price Ask Price Spread Spread % News
0.0442 0.05 0.0058 11.6% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
23 320,199 $ 0.045732 $ 14,643 301,873 0.03 - 0.075
Last Trade Time Type Quantity Stock Price Currency
12:49:01 1,111 $ 0.0442 USD

Provectus Biopharmaceuti... (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 17.27M 390.69M 373.78M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
2.51k $ - 0.00% - -

more financials information »

Provectus Biopharmaceuti... (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PVCT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.04250.0520.040.0467257156,5870.00174.0%
1 Month0.04390.0520.03820.0442178237,2760.00030.68%
3 Months0.0390.05990.030.0438817275,9430.005213.33%
6 Months0.06990.070.030.0530235341,398-0.0257-36.77%
1 Year0.0550.0750.030.0579607285,201-0.0108-19.64%
3 Years0.04510.0920.01110.0563952396,257-0.0009-2.0%
5 Years0.0350.0920.0110.0385051857,0120.009226.29%

Provectus Biopharmaceuti... (QB) Description

Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing a new class of drugs for oncology, hematology, and dermatology based on an entire, wholly-owned, family of chemical small molecules called halogenated xanthenes. Intratumoral (aka intralesional) PV-10, the first small molecule autolytic immunotherapy, which can induce immunogenic cell death, is undergoing clinical study for adult solid tumor cancers, such as melanoma and GI tumors (e.g., hepatocellular carcinoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, metastatic uveal melanoma), and preclinical study for pediatric solid tumor cancers (e.g., neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, osteosarcoma) and blood cancers (e.g., acute myeloid leukemia). Topical PH-10 is undergoing clinical study for inflammatory dermatoses (e.g., psoriasis, atopic dermatitis). Information about these and the Company's other clinical trials can be found at the NIH registry, For additional information about Provectus, please visit the Company's website at

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.